Literature DB >> 15564346

Anxiety and depression in patients with pulmonary hypertension.

Bernd Löwe1, Kerstin Gräfe, Christiane Ufer, Kurt Kroenke, Ekkehard Grünig, Wolfgang Herzog, Mathias M Borst.   

Abstract

OBJECTIVE: This is the first study that investigates the prevalence and actual treatment of anxiety, depression, and other mental disorders in patients with pulmonary hypertension (PH). The prevalence of mental disorders in patients with PH was compared with parallel groups of primary care patients and patients with inflammatory rheumatic diseases, and the relationship between functional status and prevalence of mental disorders was determined.
METHODS: The patient group with PH (70.1% female; mean age, 47.8 +/- 12.7 years) and the two comparison groups, which were matched by age and sex, consisted of 164 patients each. Patients completed self-administered instruments, including the Patient Health Questionnaire for the diagnosis of mental disorders. New York Heart Association (NYHA) functional class was assessed in all patients with PH.
RESULTS: Thirty-five percent of the patients with PH suffered from mental disorders, with the most common being major depressive disorder (15.9%) and panic disorder (10.4%). Both panic disorder and panic attacks were significantly more prevalent in patients with PH than in either patients with inflammatory rheumatic diseases or primary care patients. The prevalence of mental disorders in patients with PH increased significantly with functional impairment, from 17.7% (NYHA class I) to 61.9% (NYHA class IV). Only 24.1% of the patients with PH with mental disorders were receiving psychopharmacological or psychotherapeutic treatment.
CONCLUSIONS: Anxiety and depression are frequent in patients with PH and increase as the severity of disease progresses. Given the fact that safe and efficacious treatments of mental disorders are available, greater importance should be attached to the diagnosis and treatment of these conditions in patients with PH.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15564346     DOI: 10.1097/01.psy.0000145593.37594.39

Source DB:  PubMed          Journal:  Psychosom Med        ISSN: 0033-3174            Impact factor:   4.312


  60 in total

1.  Pulmonary arterial hypertension in the elderly: Clinical perspectives.

Authors:  Nicholas Rothbard; Abhinav Agrawal; Conrad Fischer; Arunabh Talwar; Sonu Sahni
Journal:  Cardiol J       Date:  2018-08-29       Impact factor: 2.737

2.  Rivaroxaban and macitentan can be coadministered without dose adjustment but the combination of rivaroxaban and St John's wort should be avoided.

Authors:  Andrea Huppertz; Lars Werntz; Andreas D Meid; Kathrin I Foerster; Jürgen Burhenne; David Czock; Gerd Mikus; Walter E Haefeli
Journal:  Br J Clin Pharmacol       Date:  2018-10-11       Impact factor: 4.335

3.  Depression and anxiety in patients with epilepsy, with or without other chronic disorders.

Authors:  A A Asadi-Pooya; M R Sperling
Journal:  Iran Red Crescent Med J       Date:  2011-02-01       Impact factor: 0.611

4.  Economic evaluation of exercise training in patients with pulmonary hypertension.

Authors:  Nicola Ehlken; Cora Verduyn; Henning Tiede; Gerd Staehler; Gabriele Karger; Robert Nechwatal; Christian F Opitz; Hans Klose; Heinrike Wilkens; Stephan Rosenkranz; Michael Halank; Ekkehard Grünig
Journal:  Lung       Date:  2014-03-08       Impact factor: 2.584

5.  [Pulmonary hypertension: Possible genetic causes and therapeutic options].

Authors:  E Grünig; C A Eichstaedt; N Ehlken; E Mayer; H Klose
Journal:  Herz       Date:  2015-05       Impact factor: 1.443

6.  Lower socioeconomic status is associated with worse outcomes in pulmonary arterial hypertension.

Authors:  Wen-Hui Wu; Lu Yang; Fu-Hua Peng; Jing Yao; Li-Ling Zou; Dong Liu; Xin Jiang; Jue Li; Lan Gao; Jie-Ming Qu; Steven M Kawut; Zhi-Cheng Jing
Journal:  Am J Respir Crit Care Med       Date:  2012-12-06       Impact factor: 21.405

Review 7.  Systematic Review of Health-Related Quality of Life in Patients with Pulmonary Arterial Hypertension.

Authors:  Shuyan Gu; Huimei Hu; Hengjin Dong
Journal:  Pharmacoeconomics       Date:  2016-08       Impact factor: 4.981

8.  Fibromyalgia subgroups: profiling distinct subgroups using the Fibromyalgia Impact Questionnaire. A preliminary study.

Authors:  Juliana Barcellos de Souza; Philippe Goffaux; Nancy Julien; Stephane Potvin; Jacques Charest; Serge Marchand
Journal:  Rheumatol Int       Date:  2008-09-27       Impact factor: 2.631

9.  Exercise capacity affects quality of life in patients with pulmonary hypertension.

Authors:  Michael Halank; Franziska Einsle; Stephanie Lehman; Hinrich Bremer; Ralf Ewert; Heinrike Wilkens; F Joachim Meyer; Ekkehard Grünig; Hans-Jürgen Seyfarth; Martin Kolditz; Gesine Wieder; Gert Höffken; Volker Köllner
Journal:  Lung       Date:  2013-05-17       Impact factor: 2.584

10.  The association between hypertension and depression and anxiety disorders: results from a nationally-representative sample of South African adults.

Authors:  Anna Grimsrud; Dan J Stein; Soraya Seedat; David Williams; Landon Myer
Journal:  PLoS One       Date:  2009-05-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.